This variant is extremely rare in population databases, observed at an allele frequency of 0.00040% in gnomAD v2.1 (1/251,480 alleles, no homozygotes) and 0.00012% in gnomAD v4.1 (2/1,613,376 alleles, no homozygotes), meeting PM2 at supporting strength.¹ Multiple in silico tools predict no deleterious effect: BayesDel score 0.114 falls in the benign range, and SpliceAI delta score 0.02 predicts no splicing impact, meeting BP4 at supporting benign strength. REVEL score 0.571 is borderline and does not outweigh the other two lines of evidence.² This variant has been reported in ClinVar as Uncertain Significance by three clinical laboratories (ClinVar Variation ID: 578321). Three clinical laboratories independently classified it as VUS (SCV004028319, SCV002747231, SCV000830083). No expert panel review is available.³ This variant has been observed in somatic cancers (COSMIC: COSV60689597, n=2) but lacks germline disease association evidence. Overall classification: Uncertain Significance — one supporting pathogenic criterion (PM2) and one supporting benign criterion (BP4) yield insufficient evidence to classify this variant as either pathogenic or benign. This is consistent with the ClinVar VUS classification.⁴